title: [Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz].
abstract: Efavirenz and nevirapine are frequently used drugs in antiretroviral therapy. Rashes are common side effects of these drugs. In this study, we examined the characteristics of efavirenz- and nevirapine-associated rashes. This prospective nonrandomized multicenter study included 662 HIV-infected patients (efavirenz: 325, nevirapine: 337) to determine incidence, duration, cross-reactivity, and outcome upon reexposure. Of the treated patients, 4.5% (n=30) developed rashes (nevirapine: 2.4% and efavirenz: 6.4%). In four patients treatment was not interrupted. Three patients were re-exposed to the initial drug without any side effects. Therapy with nevirapine or efavirenz does not have to be interrupted if rashes exhibit no blistering, mucosal manifestations, or systemic signs.
authors.affiliation: Hautklinik, Universität, Heidelberg. Martin_Hartmann@med.uni-heidelberg.de
authors.forename: M
authors.initials: M
authors.lastname: Hartmann
authors.forename: J
authors.initials: J
authors.lastname: Brust
authors.forename: D
authors.initials: D
authors.lastname: Schuster
authors.forename: F
authors.initials: F
authors.lastname: Mosthaf
authors.forename: M
authors.initials: M
authors.lastname: Procaccianti
authors.forename: J A
authors.initials: JA
authors.lastname: Rump
authors.forename: H
authors.initials: H
authors.lastname: Klinker
authors.forename: D
authors.initials: D
authors.lastname: Petzoldt
mesh_terms: D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use; D048588:Benzoxazines; D015897:Comorbidity; D003521:Cyclopropanes; D005076:Exanthema / Q000453:epidemiology*; D005260:Female; D005858:Germany / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care / Q000379:methods; D010078:Oxazines / Q000627:therapeutic use*; D015995:Prevalence; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D019829:Nevirapine; C098320:efavirenz
references.citation: AIDS. 2001 Sep 28;15(14):1843-8
references.pmid: 11579247
references.citation: J Am Acad Dermatol. 2002 Jul;47(1):40-6
references.pmid: 12077579
references.citation: Clin Infect Dis. 2000 Jan;30(1):227-8
references.pmid: 10619772
references.citation: Clin Infect Dis. 1998 Nov;27(5):1321-2
references.pmid: 9827291
references.citation: J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):120-5
references.pmid: 14722442
references.citation: Clin Infect Dis. 2001 Jan;32(1):124-9
references.pmid: 11118391
references.citation: Eur J Clin Pharmacol. 2003 Sep;59(5-6):457-62
references.pmid: 12920493
references.citation: HIV Med. 2004 Jan;5(1):1-10
references.pmid: 14731162
references.citation: Clin Ther. 1998 Nov-Dec;20(6):1071-92
references.pmid: 9916603
references.citation: Lancet. 2004 Apr 17;363(9417):1253-63
references.pmid: 15094269
references.citation: HIV Clin Trials. 2002 Jul-Aug;3(4):279-86
references.pmid: 12187501
references.citation: Clin Exp Allergy. 2002 May;32(5):733-5
references.pmid: 11994098
references.citation: Ann Pharmacother. 2002 Mar;36(3):430-2
references.pmid: 11895054
references.citation: Int J STD AIDS. 2005 Jun;16(6):404-9
references.pmid: 15969773
references.citation: AIDS. 1999 Mar 11;13(4):524-5
references.pmid: 10197383
references.citation: AIDS. 2001 Dec 7;15(18):2385-95
references.pmid: 11740189
references.citation: Lancet. 1998 Feb 21;351(9102):567
references.pmid: 9492778
references.citation: AIDS. 2000 Jul 28;14(11):1672-3
references.pmid: 10983663
references.citation: Hautarzt. 2003 Aug;54(8):765-6
references.pmid: 12942192
references.citation: N Engl J Med. 1993 Jun 10;328(23):1670-4
references.pmid: 8487826
references.citation: J Infect Dis. 2002 Apr 15;185(8):1062-9
references.pmid: 11930316